Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8651447 | The American Journal of Cardiology | 2018 | 22 Pages |
Abstract
Serum creatinine (sCr) was assessed at baseline and 48 to 72 hours after procedure to classify patients into 3 CI-AKI groups: Group 1: increase in sCR â¥25% over baseline but absolute increase <0.5âmg/dl; Group 2: absolute increase â¥0.5âmg/dl; Group 3: absolute increaseââ¥0.3âmg/dl orââ¥50% over baseline. The association between CI-AKI and all-cause 6-month mortality was assessed using multivariate Cox regression. Among 1,002 patients included, median age was 68 [57 to 79] years. The sample had the following characteristics: 70% men, 25% diabetics, 22% had a history of myocardial infarction, 21% had baseline estimated glomerular filtration rate (as calculated by the Modification of Diet in Renal Disease)â <60âml/min/1.72âm2, 34% had ST-segment elevation myocardial infarction, 61% underwent percutaneous coronary intervention, and 43% had multivessel disease. Based on changes in sCr, 89 patients (8.9%) were classified in Group 1; 69 (6.9%) in Group 2; and 157 (15.7%) in Group 3, whereas sCr did not increase >25% in the remaining 844 (84.2%). CI-AKI was significantly associated with 6-month all-cause mortality using the definitions for Group 2 (hazard ratio 3.1, 95% confidence interval [CI] 1.5 to 6.6, pâ=â0.002) and Group 3 (hazard ratio 2.03, 95% CI 1.03 to 4.0, pâ=â0.04), but not Group 1. In conclusion, based on the definition used for CI-AKI, CI-AKI is observed in 6% to 15.7% of patients. An increase of 25% over baseline sCr does not identify high-risk patients. CI-AKI defined as an increase in sCr >0.3âmg/dl identifies 15.7% of the population at 2-fold higher risk of mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Benoit MD, Fiona MSc, Charles Marcucci, Didier MD, PhD, Marion MD, Marc MD, Benjamin MD, Romain MD, PhD, Pierre MD, Nicolas MD, PhD, François MD, PhD,